Medicon Valley Alliance and Menarini Biotech would like to welcome you to a Good Morning Meeting 25 th of September 2024.
Menarini Biotech brings over 20 years of expertise in antibody and bioconjugation drug substance development, formulation, and drug product manufacturing to biotech companies everywhere. If you’re working with antibodies and looking to accelerate your timelines toward IND, this seminar is your opportunity. Join us to share knowledge, engage in meaningful discussions, and learn from our technical experts about the latest advancements in process development—insights that could propel your next project to success.
Date: Wednesday, 25th of September, 2024
Time: 8:30 – 11:00
Venue: Medicon Valley Alliance, Arne Jacobsens Allé 15, 2300 Copenhagen S, Denmark – Hub 2
Program
| 8:30 | Networking, registration and light breakfast |
| 9:00 | Welcome and introduction to Medicon Valley Alliance David Munis Zepernick, Director, Member Engagement & Communication, Medicon Valley Alliance |
| 9:05 | Introduction to Menarini Biotech Heiko Richtzenhain, Head of Sales and Business Development, Menarini-Biotech |
| 9:20 | From DNA to Market: Cutting edge process development of antibodies and bioconjugates Fabio D’Arata, CMC and Tech Transfer Manager Menarini Biotech Meri Gabrielli, Head of Technology Development Menarini Biotech |
| 10:30 | Q&A Session |
| 11:00 | End of Good Morning Meeting |
Speakers
 |
Fabio D’Arata, CMC and Tech Transfer Manager, Menarini Biotech
Fabio D’Arata is a seasoned professional with over 25 years of experience in the pharmaceutical industry, specializing in Chemistry, Manufacturing, and Controls (CMC) and Technology Transfer of Active Pharmaceutical Ingredients (APIs), including small molecules, biologics, and Antibody-Drug Conjugates (ADCs). He has a strong track record in leading both inbound and outbound technology transfers to international pharmaceutical companies. With extensive expertise in due diligence and business development, Fabio has played a pivotal role in the successful execution of pharmaceutical projects. His deep understanding of the CMO/CDMO market, particularly in Europe, China, and India, allows him to expertly scout, select, and allocate manufacturing projects. He excels in guiding projects through the entire process, from the Request for Proposal (RFP) and technical package preparation to final economic negotiations. Fabio’s comprehensive knowledge extends to reshoring activities and API manufacturing reallocation, as well as cost evaluation, budgeting, and cost containment strategies. His broad experience in R&D, CMC support, and regulatory procedures makes him a highly versatile and valuable asset in the pharmaceutical industry. |
 |
Meri Gabrielli, Head of Technology Development, Menarini Biotech
Dr. Meri Gabrielli graduated in Chemistry in 1997. In 2001, she obtained a PhD in Protein Chemistry from the University of Naples, Italy. In 2000, Meri started her professional career at Menarini Biotech as an Analytical Scientist with focus on protein structural characterization (including Mass Spectrometry) and Quality Control of biologics. |
| Organized by | In collaboration with |
 |
 |